/EDSA
EDSA Stock - Edesa Biotech, Inc.
Healthcare|BiotechnologyNASDAQ
$1.48+0.39%
+$0.01 (+0.39%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.63
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EDSA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.47 – $1.49
TARGET (TP)$1.70
STOP LOSS$1.36
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.08
52W High$4.49
52W Low$1.43
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-119,273 | $-186,049 | $-183,471 | $-118,188 | $-118,788 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,911,566 | $-7,014,744 | $-9,222,758 | $-18,370,790 | $-23,681,332 |
| Net Income | $-7,185,523 | $-6,170,045 | $-8,374,415 | $-17,548,924 | $-13,343,150 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.27 | $-1.93 | $-2.93 | $-8.37 | $-7.74 |
Company Overview
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EDSABeat Rate
72%
Last 18 quarters
Avg Surprise
+17.4%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
+55.4%
$-0.54vs$-1.21
Q2 24
+15.9%
$-0.58vs$-0.69
Q3 24
+10.3%
$-0.52vs$-0.58
Q4 24
+46.3%
$-0.29vs$-0.54
Q1 25
-54.8%
$-0.48vs$-0.31
Q2 25
0.0%
$-0.30vs$-0.30
Q3 25
+3.8%
$-0.25vs$-0.26
Q4 25
-18.5%
$-0.32vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-0.28 | — | — | — |
Q4 2025 | Dec 12, 2025 | $-0.27 | $-0.32 | -18.5% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.30 | $-0.30 | 0.0% | = MET |
Q1 2025 | Feb 14, 2025 | $-0.31 | $-0.48 | -54.8% | ✗ MISS |
Q4 2024 | Dec 13, 2024 | $-0.54 | $-0.29 | +46.3% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.58 | $-0.52 | +10.3% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-0.69 | $-0.58 | +15.9% | ✓ BEAT |
Q1 2024 | Feb 9, 2024 | $-1.21 | $-0.54 | +55.4% | ✓ BEAT |
Q4 2023 | Dec 15, 2023 | $-0.71 | $-0.60 | +15.5% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-1.19 | $-0.70 | +41.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.19 | $-0.84 | +29.4% | ✓ BEAT |
Q1 2023 | Feb 10, 2023 | $-1.33 | $-0.91 | +31.6% | ✓ BEAT |
Q4 2022 | Dec 16, 2022 | $-2.80 | $-0.07 | +97.5% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-2.52 | $-2.59 | -2.8% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-2.59 | $-2.31 | +10.8% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | $-2.80 | $-2.31 | +17.5% | ✓ BEAT |
Q4 2021 | Dec 28, 2021 | $-2.59 | $-1.89 | +27.0% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-2.24 | $-2.52 | -12.5% | ✗ MISS |
Latest News
Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate
📉 NegativeBenzinga•Dec 12, 2025, 09:23 PM
HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $5 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 04:00 PM
Edesa Biotech Results From Phase 3 Trial Of Paridiprubart Meets Primary, Secondary Endpoints With Statistical Significance For Reduced Mortality At 28 Days
📈 PositiveBenzinga•Oct 28, 2025, 11:50 AM
Frequently Asked Questions about EDSA
What is EDSA's current stock price?
Edesa Biotech, Inc. (EDSA) is currently trading at $1.48 per share. The stock has moved +0.39% today.
What is the analyst price target for EDSA?
No analyst price targets are currently available for this stock.
What sector is Edesa Biotech, Inc. in?
Edesa Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EDSA's market cap?
Edesa Biotech, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does EDSA pay dividends?
No, Edesa Biotech, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
IMRN
Immuron Limited
$0.94
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.65
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to EDSA for comparison